Compare CPSH & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | ESLA |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.6M | 60.9M |
| IPO Year | 1995 | N/A |
| Metric | CPSH | ESLA |
|---|---|---|
| Price | $4.46 | $1.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | 362.6K | ★ 379.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.87 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | $149.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $0.73 |
| 52 Week High | $6.85 | $3.15 |
| Indicator | CPSH | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 49.76 |
| Support Level | $4.36 | $1.15 |
| Resistance Level | $4.89 | $1.53 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 26.70 | 47.27 |
CPS Technologies Corp provides material solutions to the transportation, automotive, energy, computing/Internet, telecommunications, aerospace, defense, and oil and gas end markets. Its primary material solution is metal matrix composites (MMCs), which are a class of materials consisting of a combination of metal and ceramic. The company designs, manufactures and sells custom MMC components, which manages the performance and reliability of systems in the end markets. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.